For example, trametinib inhibition of the MEK-ERK pathway in many tumor cells leads to a rapid degradation of c-MYC and transcriptional reprogramming that in some tumor cells can be 15–20% of the transcriptome, effectively changing the tumor cell phenotype (28, 29). This evidence concerns the gene MYC and neoplasm.